Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2527-2529

  Li, Jian ^a   Zhang, Wei ^a   Kang, Wen Ying ^a   Cao, Xin Xin ^a   Duan, Ming Hui ^a   Zhou, Dao Bin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BORTEZOMIB; CARBON MONOXIDE; CREATININE; DEXAMETHASONE; FUROSEMIDE; IMMUNOGLOBULIN A; MELPHALAN; POTASSIUM; SERUM ALBUMIN; VASCULOTROPIN;

ADULT; ALBUMIN BLOOD LEVEL; ASCITES; BONE MARROW BIOPSY; CASE REPORT; CONSOLIDATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ELECTROPHORESIS; FOLLOW UP; GYNECOMASTIA; HEMANGIOMA; HEPATOSPLENOMEGALY; HUMAN; HYPERPIGMENTATION; HYPERPROLACTINEMIA; HYPOTENSION; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY FUNCTION; LEG EDEMA; LETTER; LUNG DISEASE; LUNG FUNCTION; MALE; NEUROPATHY; PHYSICAL EXAMINATION; PLASMA CELL; PLEURA EFFUSION; POEMS SYNDROME; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINE VOLUME;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; POEMS SYNDROME; PYRAZINES; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84868381449     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.690515     Document Type: Letter

References (17)

1. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, riskstratification, and management. Am J Hematol 2011;86:591-601.
2. Li J, Zhou DB, Huang Z, et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 2011;90:819-826.
3. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004;104:3400-3407. (Pubitemid 39507165)
4. Li J, Zhang W, Li J, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011;117:6445-6449.
5. Tang X, Shi X, Sun A, et al. Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009;83:609-610.
6. Kaygusuz I, Tezcan H, Cetiner M, et al. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 2010;84:175-177.
7. Ohguchi H, Ohba R, Onishi Y, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Ann Hematol 2011;90:1113-1114.
8. Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 2010;89:217-219.
9. Wang X, Ye S, Xiong C, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol 2011;41:1221-1224.
10. Warsame R, Kohut IE, Dispenzieri A. Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. Eur J Haematol 2012 Mar 14. [Epub ahead of print]
11. Graham RC, Hughes R. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006;77:973-976. (Pubitemid 44174089)
12. Nakamoto Y, Imai H, Yasuda T, et al. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 1999;14:2370-2378. (Pubitemid 29462474)
13. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 2011;7:36-44.
14. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496-2506. (Pubitemid 36857604)
15. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008;22:842-849. (Pubitemid 351552634)
16. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593-1599.
17. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of onceweekly bortezomib in multiple myeloma patients. Blood 2010;116: 4745-4753.